Myomo (MYO) Cash from Financing Activities (2016 - 2025)
Myomo's (MYO) quarterly Cash from Financing Activities came in at -$50000.0 in Q3 2025, up 74.94% on a YoY basis from -$28581.7 in Q3 2024, and down 101.25% quarter-over-quarter from $4.0 million in Q2 2025.
Powered by 
Analysis
Myomo (MYO) Cash from Financing Activities (2016 - 2025) Analysis & Trends
Myomo (MYO) has reported Cash from Financing Activities for 10 consecutive years, with -$50000.0 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Cash from Financing Activities rose 74.94% year-over-year to -$50000.0; the trailing twelve-month figure through Sep 2025 stood at $19.7 million (up 281.28% YoY), and the FY2024 full-year result was $20.9 million, up 115.5% from the prior year.
- Cash from Financing Activities retreated to -$50000.0 in Q3 2025 per MYO's latest filing, from $4.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $15.8 million in Q4 2024 and bottomed at -$199500.0 in Q3 2024.
- Historically, Cash from Financing Activities has averaged $3.2 million across 5 years, with a median of $1.1 million in 2021.
- The widest YoY moves for Cash from Financing Activities: up 50870932.26% in 2024, down 105.05% in 2024.
- Over 5 years, Cash from Financing Activities stood at $4.8 million in 2021, then slumped by 92.12% to $376858.0 in 2022, then slumped by 99.99% to $31.0 in 2023, then surged by 50870932.26% to $15.8 million in 2024, then slumped by 100.32% to -$50000.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$50000.0, $4.0 million, and -$36506.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | -343.00 Mn |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | -95.00 Mn |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | -410.00 Mn |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | -300,000.00 |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | -510.00 Mn |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | -607.30 Mn |
| 9 | Steris | 21.90 Bn | 21.43 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Myomo | 54.96 Mn | 35.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -50,000.00 |
| Jun 30, 2025 | 4.00 Mn |
| Mar 31, 2025 | -36,506.00 |
| Dec 31, 2024 | 15.77 Mn |
| Sep 30, 2024 | -199,500.00 |
| Mar 31, 2024 | 5.36 Mn |
| Dec 31, 2023 | 31.00 |
| Sep 30, 2023 | 3.95 Mn |
| Jun 30, 2023 | -8,147.00 |
| Mar 31, 2023 | 5.77 Mn |
| Dec 31, 2022 | 376,858.00 |
| Dec 31, 2021 | 4.78 Mn |
| Sep 30, 2021 | 1.10 Mn |
| Jun 30, 2021 | 1,208.00 |
| Mar 31, 2021 | 7.29 Mn |
| Dec 31, 2020 | 18,923.00 |
| Sep 30, 2020 | 4.37 Mn |
| Jun 30, 2020 | 672,710.00 |
| Mar 31, 2020 | 11.71 Mn |
| Dec 31, 2019 | 2.79 Mn |